Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review
Pediatric Dermatology · 2026-03 · 43 (2) · 411-414
DOI: 10.1111/pde.70038 ↗Abstract
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of systemic steroids. Although limited by the small sample size and lack of high‐quality data, omalizumab presents as a well‐tolerated and potentially effective steroid‐sparing agent for pediatric cutaneous mastocytosis.
EUVIMED